Agu

RT's are not endorsements

[Agu @agunan_k]

Excited to see JBI-802 featured at #ASH26 The emerging clinical data continue to strengthen our conviction in its potential to deliver meaningful benefit for patients with MPNs. Looking forward to the discussions at #ASH2026 and to what comes next.

[Agu @agunan_k]

@CNBCTV18News Challenging authority for 'what is right' is true heroism...Salute Mam!!

[Agu @agunan_k]

@Nyx_Tech_AI Gemini

[Agu @agunan_k]

@Akshita_N Seriously, NO shame, NO embarassment just shamelessly feed false information driving an agenda

[Hidehito HORINOUCHI @HHorinouchi]

🆙#WCLC26 #LCSM Oral Session
🔥DeLLphi-309: Tarlatamab Extended-Interval Dosing Regimens in Patients With SCLC: The Randomized Phase 2 Study
🎙️Dr. Jonathan W. Goldman
🎯Tarlatamab extended-interval dosing may offer flexibility
🔢OA05.01
☑️NCT06745323
🔗 https://t.co/a4bS3HH6g4
@OncoAlert @Larvol @IASLC

[Paras Sharma @paras_biotech]

ADC field's uneven maturity: Diversification in targets, consolidation in payloads

Source: https://t.co/YVsfkglVK5

[Timothée Olivier, MD @Timothee_MD]

Adagrasib was just withdrawn by the @FDA in metastatic colorectal cancer based on the negative results in KRYSTAL-10

"A waterfall plot can look impressive, and high response rates can create enthusiasm, but they should not be confused with proven clinical benefit."

From Sahar van Waalwijk, new guest post in
https://t.co/P3NUOebqBF !

[Jacob Plieth @JacobPlieth]

$ABBV RC148 (ABBV-1480) + chemo in 1st-line NSCLC.
Squam: ORR 90%, PD-L1<1% ORR 93%, "exceeding $SMMT ivonescimab's 71% in Harmoni-6".
Non-squam: ORR 76%, PD-L1<1% ORR 71%.
#WCLC26

[Hidehito HORINOUCHI @HHorinouchi]

🔥Pulmonary toxicities of ADCs in SCLC & NSCLC: systematic review & meta-analysis
🆙 @JTOonline
☑Any-grade pulmonary AEs 30.9%; grade ≥3 6.9%; pneumonitis/ILD 8.0%
🎯Pulmonary AEs more frequent in SCLC than NSCLC (52.1% vs 22.5%)
🎯Pneumonitis more common in NSCLC than SCLC (12.1% vs 2.8%)
🎙 @Rparedes_MD @ChristianRolfo
#LCSM #ADC @OncoAlert @Larvol
https://t.co/MNXlUp25kR

[Eric Topol @EricTopol]

A state-of-the science 5 ★ review of MASH (fatty liver with inflammation, nonalcoholic). Awareness of this important, highly prevalent, often undiagnosed condition has increased in recent years, and now the interventions to go after it have blossomed (Figure)
@Nature @CancerInflam @GallageSuchira
https://t.co/zjECh6YSYJ

[Yakup Ergün @dr_yakupergun]

Renal cell carcinoma: molecular understanding and therapeutic development

Great review👇

https://t.co/noZev6Lqmh

[Eric Topol @EricTopol]

We need to rev it up. Cancer vaccines.
https://t.co/mhpvWrqmZk @Nature

[nature @Nature]

The US FDA have now approved this drug for use against a cancer previously thought to be "undruggable"

https://t.co/GvhrbH8mYv

[Agu @agunan_k]

@sumanthraman Questioning it even after great @Ahmedshabbir20 is quoting the report? He is one among the few living unbiased journalist

[Muthukrishnan Dhandapani @dmuthuk]

If the decision is not to go ahead with Parandur Airport, so be it.

But why set false narratives with half baked reports like this?

Even if we develop Parandur Airport, $1.5 trillion by 2036 remains only an aspirational goal. To make it a reality, the state has to sweat it out and fire on all cylinders.

Time to focus more on execution than on setting narratives.

[Dr. John Cush @RheumNow]

VA study of 4108 RA-ILD (2006-21). PRED use was 65-77%, A& 1st line Rx (MMF, AZA, RTX, CTX) incr after ILD, use was low (1.2-12%). MTX decr (47 to 30%), but LEF, TNFi, ABA incr. Predictors of ILD Rx: FVC, CCP+, ILD Dx after 2012. https://t.co/GT3Vwo11w1

[Agu @agunan_k]

@indiatodaytamil Absolute zero respect for the regional language on display here. Would @IndiaToday ever dare to recruit an anchor with such poor language skills or pronunciation for their Hindi or English channels? Treating regional language audiences as an afterthought is unacceptable.

[Dana-Farber @DanaFarber]

A 40-year goal in cancer research is coming closer to reality as an experimental personalized cancer vaccine from @moderna_tx and @Merck is showing promise in helping prevent cancer from returning or spreading in high-risk melanoma patients

But how does a cancer vaccine actually work? Watch to hear Ann Silk, MD, explain the science. ⬇️ https://t.co/d0ZIcAnmhW

[Vivek Subbiah, MD @VivekSubbiah]

🚨⭐️Sharing for your Sunday morning read 👉🏼Beyond one gene, one target: Next-generation precision oncology: Trends in Cancer @trendscancer @Dr_R_Kurzrock @OncoAlert @oncodaily
https://t.co/88607NDa4t

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Our group’s new paper Clinical outcomes associated w/#NPM1 mutations in newly diagnosed AML - Farhat - 2026 - @JournalCancer https://t.co/UgFg3OXh2N | Farhat A & @GhayasIssa | @sanamloghavi @DanielleHammo20 @Daver_Leukemia @doctorpemm @TapKadia | @UTMDAnderson #endcancer